[HTML][HTML] Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy.
S Karageorgopoulou, ID Kostakis, M Gazouli… - BMC cancer, 2017 - Springer
Background Recognizing resistance or susceptibility to the current standard cisplatin and
paclitaxel treatment could improve therapeutic outcomes of metastatic or recurrent cervical
cancer. Methods Forty-five tissue samples from patients participating in a phase II trial of
cisplatin and ifosfamide, with or without paclitaxel were collected for retrograde analysis.
Immunohistochemistry and genotyping was performed to test ERCC1, III β-tubulin, COX-2,
CD4, CD8 and ERCC1 (C8092A and N118 N) and MDR1 (C3435T and G2677 T) gene …
paclitaxel treatment could improve therapeutic outcomes of metastatic or recurrent cervical
cancer. Methods Forty-five tissue samples from patients participating in a phase II trial of
cisplatin and ifosfamide, with or without paclitaxel were collected for retrograde analysis.
Immunohistochemistry and genotyping was performed to test ERCC1, III β-tubulin, COX-2,
CD4, CD8 and ERCC1 (C8092A and N118 N) and MDR1 (C3435T and G2677 T) gene …
以上显示的是最相近的搜索结果。 查看全部搜索结果